PHLPP (PH domain leucine-rich repeats protein phosphatase) represents a family of novel Ser/Thr protein phosphatases. Two highly related isoforms in this family, PHLPP1 and PHLPP2, have been identified to serve as negative regulators of Akt and protein kinase C by dephosphorylating the kinases directly. In this study, we examined the expression pattern of both PHLPP isoforms in colorectal cancer specimens and the adjacent normal mucosa using immunohistochemical staining. We found that the expression of PHLPP1 or PHLPP2 isoform was lost or decreased in 78 and 86% of tumor tissues, respectively. Stable overexpression of either PHLPP isoform in colon cancer cells decreased the rate of cell proliferation and sensitized the cells to growth inhibition induced by the phosphoinositide-3 kinase inhibitor, LY294002, whereas knockdown of either PHLPP isoform by shRNA promoted the proliferation of DLD1 cells. In addition, we demonstrated that the PHLPP-mediated growth inhibition in colon cancer cells was largely rescued by overexpression of a constitutively active Akt. Moreover, reexpression of either PHLPP isoform in HCT116 cells inhibited tumor growth in vivo. Taken together, our results strongly support a tumor suppressor role of PHLPP in colon cancer.
Introduction
Dysregulation of signaling pathways mediated by phosphoinositide-3 kinase (PI3K) and protein kinase C (PKC) has been implicated in the development of colorectal cancer (Gokmen-Polar et al., 2001; Samuels et al., 2004 Samuels et al., , 2005 . Serving as a major regulator downstream of PI3K, Akt promotes tumor growth by promoting cell proliferation and inhibiting apoptosis (Manning and Cantley, 2007) . In addition, upregulation of PKC bII contributes to tumorigenesis of colon cancer by inducing hyperproliferation (Murray et al., 1999; Gokmen-Polar et al., 2001) . Both Akt and PKC belong to the AGC kinase superfamily and share three highly conserved phosphorylation sites namely the activation loop, turn motif and hydrophobic motif sites (Newton, 2003) . Phosphorylation of Akt is required for the activation of the enzyme following activation of PI3K, whereas phosphorylation of PKC does not control the enzyme activity directly rather it is constitutive and necessary for maintaining the stability of the protein (Newton, 2003) . As the activity and the total protein expression of Akt and PKC are controlled by phosphorylation, dephosphorylation leads to effective signaling termination by either inactivating the enzyme directly or by decreasing the functional lifetime of the protein. However, the phosphatases responsible for dephosphorylating the AGC kinases are largely elusive.
Recently, a family of novel protein phosphatases, namely PHLPP (PH domain leucine-rich repeats protein phosphatase), have been identified as the phosphatases for Akt and PKC. Two isoforms, PHLPP1 and PHLPP2, found in this family, share their ability to dephosphorylate both Akt and PKC directly (Gao et al., 2005; Brognard et al., 2007) . Specifically, overexpression of PHLPP results in a decrease of Akt activity and an increase of apoptosis in non-small-cell lung cancer (H157) and breast cancer cells, whereas knockdown of PHLPP shows an opposite effect (Gao et al., 2005; Brognard et al., 2007) . However, as phosphorylation of PKC is required for maintaining the protein stability, PHLPP-mediated dephosphorylation dictates the expression level of PKC and knockdown of PHLPP delays phorbol ester-induced PKC downregulation (Gao et al., 2008) . Thus, by controlling the phosphorylation status of Akt and PKC, PHLPP plays an important role in regulating the duration and amplitude of signals evoked by these kinases.
Several lines of evidence suggest that PHLPP functions as a tumor suppressor. For example, it has been shown that overexpression of PHLPP1 in a glioblastoma cell line inhibits the tumor growth in xenografted nude mice (Gao et al., 2005) , and decreased expression of PHLPP has been linked to the metastatic potential of 21T breast cancer cells (Qiao et al., 2007) . However, a direct association of PHLPP and human cancers has not been established. In the present study, we aimed to elucidate the functional connection of PHLPP to colon cancer. Furthermore, the ability of both PHLPP isoforms in antagonizing tumor growth was determined in vivo.
Results

Loss of PHLPP expression in colorectal cancer patient specimens
To explore the link between PHLPP and human colorectal cancer, we examined the potential loss of PHLPP expression in colorectal cancer specimens. Colon cancers from both the left and the right sides and the adjacent normal mucosa were analysed for expression of PHLPP. The expression of both PHLPP isoforms was the highest in the surface epithelium of normal colonic mucosa, but largely excluded from the bases of the crypts (Figures 1a and b ). Interestingly, PHLPP1 was concentrated at the lateral membrane of the epithelial cells (Figure 1a ), whereas PHLPP2 has mixed cytoplasmic and nuclear expression ( Figure 1b ). The specificity of the PHLPP antibodies was confirmed by including the blocking peptides in the immunohistochemical (IHC) staining. The quantitative results based on a four-tier scoring system revealed that the expression of either PHLPP1 or PHLPP2 was lost or decreased in the cancer samples (median PHLPP1 and PHLPP2 staining score ¼ 1.0) relative to adjacent normal colonic mucosa (median PHLPP1 and PHLPP2 ¼ 3.0) (Po0.0001). The detailed statistics of the IHC staining results are summarized in Table 1 . As shown in Figure 1c , the majority of the normal tissues showed high expression of PHLPP1 and PHLPP2 (100 and 96%, respectively). In marked contrast, the expression of PHLPP1 or PHLPP2 was significantly lost or decreased in 78 and 86% of tumor tissues, respectively (Po0.0001). Interestingly, there was a significant positive correlation of intensity staining score between the two isoforms (r ¼ 0.75, Po0.0001; Table 2 ), suggesting that loss of both PHLPP isoforms was commonly observed in the same patient. Therefore, the two PHLPP isoforms may function together to inhibit tumorigenesis. Taken together, these findings suggest that loss of PHLPP expression occurs at a high frequency in colorectal cancers strongly supporting a tumor suppressor role of PHLPP.
Overexpression of PHLPP inhibits proliferation of colon cancer cells
To address the functional importance of maintaining PHLPP expression in colon cancer cells, we first analysed the basal PHLPP expression and Akt phos-phorylation in three colon cancer cell lines. As shown in Figure 2a , the endogenous expression of both PHLPP isoforms was the highest in DLD1 cells. Interestingly, the phosphorylation of Akt was lower in DLD1 compared to that of HCT116 and HT29 cells. Note that there are two splicing variants of the PHLPP1 gene with molecular mass of 140 and 190 kDa expressed as reported previously (Brognard et al., 2007) . The longer form (PHLPP1b) contains the entire coding sequence of the shorter form (PHLPP1a) with an additional 5 0 extension. The two PHLPP1 isoforms are expected to have similar phosphatase activity as the majority of the protein sequences are shared. However, the cloning of PHLPP1b cDNA has not been reported to date. Here, we focused our studies on the functional effect of PHLPP1a (we referred to it as PHLPP1 to remain consistent with the nomenclature used previously (Gao et al., 2005; Brognard et al., 2007) ).
As both HCT116 and HT29 cells have reduced expression of PHLPP, we established stable cell lines overexpressing either PHLPP isoform and investigated the functional effect of reintroducing PHLPP into these cells. To determine the rate of proliferation, the numbers of cells were counted daily for 4 days. Overexpression of either PHLPP isoform significantly slowed the rate of proliferation in both HCT116 and HT29 stable cells lines. Specifically, the numbers of cells were reduced to 45 and 50% at day 4 in HCT-P1 and HCT-P2 cells, and 31 and 42% in HT29-P1 and HT29-P2 cells compared to the control cells, respectively ( Figure 2b ). To further determine whether PHLPP inhibits cell proliferation by interfering with the cell cycle, we examined the cell-cycle parameters of HCT116 stable cells using fluorescenceactivated cell sorting analysis, and the representative results are shown in Figure 2c . Overexpression of PHLPP1 resulted in an increase in the percentage of cells in the G 2 phase suggesting a potential block of the G 2 /M transition in the cell cycle. Interestingly, overexpression of PHLPP2 induced a G 1 arrest as measured by increased G 1 /S ratio but had no effect on the numbers of G 2 cells (Figure 2d ). In addition, expression of either PHLPP isoform had a more pronounced effect under the serum-starved condition (ÀS). These cancer cells are known to be resistant to serum starvation due to lack of ability to shut down of growth signals completely, however, they are able to turn off those signals more effectively in the presence of PHLPP. Overexpression of PHLPP alone was unable to induce a significant amount of apoptosis as indicated by the absence of cell population in the sub-2N fractions ( Figure 2c ). Furthermore, we tested the synergistic effect of PHLPP expression on cell proliferation in the presence of the PI3K inhibitor, LY294002. Treating cells with LY294002 inhibited the proliferation of HCT-Con cells in a concentration-dependent manner. Overexpression of either PHLPP isoform significantly enhanced the inhibitory effect of LY294002 at 12 and 16 mM (Figure 2e ), suggesting that the level of PHLPP expression in colon cancer cells is an important factor in determining the sensitivity to PI3K inhibition. Taken together, these results suggest that both PHLPP Colorectal cancers with proximal, transverse or distal tumors and adjacent normal mucosa were analysed for expression of PHLPP1 and PHLPP2 isoforms using immunohistochemical (IHC) staining. (a and b) Representative images taken from the normal and tumor specimens stained with the PHLPP isoform-specific antibodies. Images shown in the upper panels were obtained with a Â 10 objective, and the enlarged images of areas enclosed by the blue boxes are shown in the panels directly below. The images in the right most panels were taken from the normal specimens stained with the PHLPP antibodies that were preabsorbed with the peptide antigens. (c) Quantitative representation of summarized results obtained from the IHC staining experiments. The intensity of staining for each protein was scored with a four-tier system (0-3) (Reiner et al., 1990) . A total of 16 sets of pair-matched samples (from 16 patients) were included. Additional samples screened are in the format of tissue arrays that contain tumor tissue sections from 40 colon cancer patients and 8 normal colon tissue sections. Thus, the total numbers of normal samples screened are 24 and the tumor samples are 55 for PHLPP1 and 56 for PHLPP2. The pie charts indicate the percentage of samples in each tier category.
isoforms inhibit cell proliferation primarily by interfering with the different cell-cycle checkpoints in colon cancer cells.
PHLPP modulates both Akt and PKC pathways in colon cancer cells
It has been reported previously that PHLPP serves as a phosphatase for both Akt and PKC. We next determined which pathway is regulated by PHLPP in colon cancer cells. To assess the effect of PHLPP on Akt signaling, the phosphorylation of Akt and a number of Akt substrates were examined in stable HCT116 and HT29 cells. As PHLPP controls the level of PKC expression, the total PKC expression was analysed as well. In HCT116 stable cells, Akt phosphorylation at the Ser473 site was decreased significantly by B70% in both PHLPP1 and PHLPP2 overexpressing cells, whereas the Thr308 site was only slightly affected (Figures 3a and b ). This is consistent with the notion that PHLPP prefers the hydrophobic motif site (Ser473) on Akt (Gao et al., 2005; Brognard et al., 2007) . In addition, dephosphorylation of Akt substrates including TSC2 (at an inhibitory phosphorylation site) and p27 was detected in HCT-P1 and HCT-P2 cells (Figures 3a and b ). Because overexpression of PHLPP affects the cell cycle as shown in Figure 2 , the total protein expression of p27 was analysed as well. The results showed that the expression level of p27 was increased by B50% in both HCT-P1 and HCT-P2 cells (Figures 3a and b) . In contrast, phosphorylation of another Akt substrate, GSK3 (including both aand b-isoforms), was not altered in PHLPP expressing cells. Furthermore, as elevation of PKC bII has been implicated in colon cancer carcinogenesis, we determined whether the expression of PKC bII was modified by PHLPP. Indeed, the expression of PKC bII was reduced by B30% in both HCT-P1 and HCT-P2 cells (Figures 3a and b ). Serving as a control, the level of PKC-z, a PHLPPinsensitive PKC isozyme (due to lack of phosphorylation in the hydrophobic motif (Gao et al., 2008) ), was not altered by PHLPP expression.
To confirm the results obtained in HCT116 cells, we examined the effect of PHLPP overexpression in HT29 stable cells. Similarly, dephosphorylation of Akt and its substrates TSC2 and p27, as well as increased expression of p27, was readily detected in HT29-P1 and HT29-P2 cells. In addition, downregulation of PKC bII but not PKC-z was observed (Figures 3c and d) . Moreover, we found that the mRNA level of p27 and PKC bII was not altered by overexpression of PHLPP ( Supplementary  Figure 1) suggesting a post-transcriptional modulation mediated by PHLPP. Collectively, these data indicate that overexpression of PHLPP selectively regulates Akt and a subset of Akt substrates, as well as altering the expression of PKC bII in colon cancer cells.
PHLPP-mediated growth inhibition is rescued by overexpressing an active mutant of Akt
As overexpression of PHLPP negatively regulates both Akt and PKC as shown in Figure 3 , we performed rescue experiments to dissect the relative contribution of each pathway. If PHLPP-induced inhibitory effect was mediated through Akt, overexpression of a PHLPPresistant Akt (phosphomimetic mutation at Ser473) should release the cells from growth inhibition. Because the PI3K/Akt pathway is basally activated due to the existence of a mutant PIK3CA allele in HCT116 cells (Samuels et al., 2005) , overexpression of Akt/S473D only resulted in a moderate increase (B15%) of cell proliferation in control cells. However, the rate of proliferation was increased by B2-fold in HCT-P1 and HCT-P2 cells on Akt/S473D expression ( Figure 4a ). Similar experiments were performed to examine whether PHLPP overexpressing cells could be rescued by PKC bII. Overexpression of PKC bII resulted in a B30% increase in cell numbers in HCT-Con cells (consistent with the role of PKC bII in promoting proliferation), however, only a 10-15% increase of cell numbers was observed in HCT-P1 and HCT-P2 cells (Figure 4b ). Collectively, these data suggested that the inhibitory effect of PHLPP was largely explained by PHLPPmediated inactivation of Akt, as more than two-thirds of the inhibition was released by Akt/S473D expression. On the other hand, although overexpression of PHLPP induces downregulation of PKC bII, it has little contribution under our experimental conditions.
Functional effect of knocking down endogenous PHLPP in colon cancer cells
To examine the effect of knocking down endogenous PHLPP in colon cancer cells, we infected DLD1 cells (which have the highest basal PHLPP expression) with lentivirus-based shRNAs targeting PHLPP1 or PHLPP2. Two different targeting constructs were 
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Normal tissue (n ¼ 24) 3.0 (2.0-3.0) 2.92 ± 0.28 Tumor tissue (n ¼ 55) Note: There was a statistically significant positive correlation between PHLPP1 and PHLPP2 in the tumor tissue (r ¼ 0.75, Po0.0001) whereas this correlation between the two proteins did not hold true for normal tissue (r ¼ 0.30, P ¼ 0.16).
chosen for each PHLPP isoform (sh-P1-97 and sh-P1-94 for PHLPP1; sh-P2-60 and sh-P2-59 for PHLPP2). A control virus was used to create the control cell lines. The knockdown efficiency was around 60-80% for PHLPP1 and 50-90% for PHLPP2 ( Figure 5a ). In the stable knockdown cells, an increase of PKC bII expression was consistently observed, whereas the level of PKC-z was unchanged (Figure 5a ). To determine the effect of PHLPP knockdown on Akt phosphorylation, the stable knockdown cells (sh-P1-97 and sh-P2-60 were chosen because the knockdown efficiency was higher) were subjected to different growth conditions ( Figure 5b ). The phosphorylation of Akt was approximately 1.5-to 2-fold higher in the PHLPP knockdown Figure 5c ). Specifically, the numbers of cells were 53 and 66% higher than those of the control cells at day 4 for sh-P1-97 and sh-P2-60, or 40 and 34% higher for sh-P1-94 and sh-P2-59, respectively. Taken together, our results underscore the importance of maintaining the level of PHLPP expression as PHLPP has a critical function in keeping a tight control of growth signals in colon cancer cells.
Overexpression of PHLPP inhibits tumor growth in xenografted nude mice
To examine whether increased PHLPP expression in colon cancer cells affects their tumorigenic ability in vivo, we injected HCT-Con, HCT-P1 and HCT-P2 cells subcutaneously into the nude mice and monitored tumor growth. HCT-Con cells formed tumors Figure 3 Overexpression of PHLPP (PH domain leucine-rich repeats protein phosphatase) negatively regulates both Akt and protein kinase C (PKC) bII in colon cancer cells. Western blots of cell lysates prepared from the PHLPP overexpressing stable cells were analysed using the following antibodies to show the phosphorylation status or the total protein expression: PHLPP1, PHLPP2, P473, P308, Akt, phospho-TSC2 (T1462 site, p-TSC2), phosph-p27 (T157 site, p-p27), p27, phospho-GSK3 (S21/S9 sites, p-GSK3), PKC bII, PKC-z and g-tubulin antibodies. (a) PHLPP-mediated regulation of Akt, Akt substrates and PKC in HCT-Con, HCT-P1 and HCT-P2 cells (lanes 1-3). (b) Graphs showing quantified data from three independent experiments as shown in (a). (c) PHLPPmediated regulation of Akt, Akt substrates and PKC in HT29-Con, HT29-P1 and HT29-P2 cells (lanes 1-3). (d) Graphs showing quantified data from three independent experiments as shown in (c). The ECL signals were captured and quantified using a FluorChem digital imager (Alpha Innotech, San Leandro, CA, USA). For all graphs shown, relative phosphorylation of Akt at Ser473 (P473/Akt) or T308 (P308/Akt) was determined by normalizing ECL signals of the P473 or P308 antibodies to those of the Akt antibody, and the relative p27 and PKC bII expression was calculated by normalizing ECL signals of the p27 or PKC bII antibodies to those of tubulin. The control cells (Con) were set to 1, and two-sample t-tests were performed to compare the difference between the PHLPP overexpressing cells and the control cells. Data represent mean ± s.e.m. (n ¼ 3; # Po0.001 and *Po0.05).
effectively, and the tumor size reached approximately 400 mm 3 within 28 days. In marked contrast, the ability of HCT-P1 and HCT-P2 cells to form tumors was significantly reduced over the same period (Figure 6a ). Only small tumors with size less than 100 mm 3 were detected at the end of the experiments (Figure 6a ). To determine whether PHLPP suppressed tumor growth by decreasing the rate of proliferation, we measured the numbers of Ki-67-positive cells (proliferating cells) in the tumor sections ( Figure 6b ). The results revealed that the numbers of cells stained positive for Ki-67 were significantly reduced by 44 and 55% in tumors formed by HCT-P1 and HCT-P2 cells, respectively. Furthermore, the levels of PHLPP expression and Akt phosphorylation in the tumor sections were analysed using IHC staining. A modest increase in PHLPP expression was detected in the corresponding tumor sections, whereas the phosphorylation level of Akt was markedly decreased in tumors derived from HCT-P1 and HCT-P2 cells compared to that of HCT-Con cells (Figure 6c ). Taken together, the in vivo experiments demonstrate that overexpression of either PHLPP isoform inhibits tumorigenesis of colon cancer cells in nude mice, and this inhibition is largely attributed to PHLPPmediated negative regulation of cell proliferation.
Discussion
Controlling the balance of protein phosphorylation is one of the most important defense mechanisms provided by protein phosphatases to prevent aberrant hyperactivation of signaling in cells. Our studies here focused on elucidating the tumor suppressor function of two closely related protein phosphatases, PHLPP1 and PHLPP2, in colon cancer. We found that loss of PHLPP expression is associated with 70-80% of patient samples. Overexpression of either PHLPP in colon cancer cells decreases the rate of cell proliferation, sensitizes the cells to PI3K inhibitor and antagonizes the tumorigenesis process in nude mice. Although both Akt and PKC are modulated by PHLPP, the rescue experiments indicate that PHLPP-mediated growth inhibition is largely due to its negative regulation of Akt signaling. The tumor suppressor function of PHLPP has been suggested based on the initial findings that both PHLPP isoforms serve as negative regulators of Akt (Gao et al., 2005; Brognard et al., 2007) . In this study, we provide the first direct evidence linking PHLPP to colon cancer. Intriguingly, we did not find an inverse correlation between loss of PHLPP expression and cancer stage. It is possible that loss of PHLPP expression provides growth advantage for tumor cells at early stages, however, PHLPP may have a different function in cancer metastasis during the late stage of tumor, as this is the case for Akt1 and Akt2 in the tumorigenesis and metastasis processes of breast cancer (Yoeli-Lerner et al., 2005; Maroulakou et al., 2007) . Interestingly, the highest expression of both PHLPP isoforms was found in the fully differentiated cells in the upper crypts of the normal colonic mucosa. In agreement with our findings, it has been shown that mRNA of the PHLPP2 gene is preferentially localized to the villi of the small intestine using microarray analysis (Kosinski et al., 2007; Saaf et al., 2007) . This differential expression pattern of PHLPP is consistent with its role in inhibiting cell proliferation and promoting apoptosis, as the epithelial cells lose their ability to proliferate and begin to undergo apoptosis as they reach the tip of the villus. Future studies with a larger and more comprehensive Figure 4 Overexpression of an active form of Akt but not protein kinase C (PKC) bII alleviates PHLPP (PH domain leucine-rich repeats protein phosphatase)-mediated growth inhibition. HCT-Con, HCT-P1 and HCT-P2 stable cells were transiently transfected with vector or Akt mutant S473D in (a); and transfected with vector or PKC bII in (b). For all data points, equal numbers of transfected cells were reseeded approximately 16 h after transfection and allowed to grow for 72 h. The cells were then fixed and stained with crystal violet, washed and the absorbance at 570 nm was measure. The two-sample t-tests were performed to compare the difference between the vector and Akt/S473D or PKC bIItransfected cells. Data represent mean±s.e.m. (n ¼ 3; z Po0.01). The blot insert in the graph (a) shows the expression of Akt, and the blot insert in the graph (b) shows the expression of PKC bII in the transfected cells. Note that as the cellular PKC activity is determined by the total PKC expression rather than the phosphorylation status, overexpression of wild-type PKC bII is sufficient to increase the amount of kinase available in cells. The expression construct used here encodes a rat PKC bII protein that has a slightly smaller molecular weight than the endogenous human homologue.
sample set are required to address fully whether loss of PHLPP expression is tumor stage and differentiation status dependent.
Our data here indicate that cancer cells with reduced levels of endogenous PHLPP are more sensitive to reintroduction of PHLPP into the cells, and only a modest overexpression of PHLPP is enough to induce dephosphorylation of Akt effectively. On the other hand, if the level of endogenous PHLPP is already reduced basally, we found that further reduction of PHLPP expression by RNAi has limited effect on cell proliferation. In addition, knockdown of both PHLPP isoforms together by transiently transfecting cells with siRNAs did not enhance the effect of knocking down any single PHLPP isoform in DLD1 cells (data not shown). This may be due to the negative feedback control of the Akt pathway through p70S6K (Manning et al., 2005; Manning and Cantley, 2007) , therefore, any hyperactivation of Akt beyond a certain threshold (as a result of knocking down both PHLPP isoforms) is Stable knockdown cells were created to deplete expression of PHLPP1 or PHLPP2 in DLD1 cells. Cell lysates prepared from Con, sh-P1-97, sh-P1-94, sh-P2-60 and sh-P2-59 cells (lanes 1-5) were analysed using western blotting. The following antibodies were used: PHLPP1, PHLPP2, PKC bII, PKC-z and g-tubulin antibodies. (b) DLD1 stable knockdown cells including Con, sh-P1-97 and sh-P2-60 cells were either kept overnight in either serum-containing media ( þ S, lanes 1-3), serum-free media (ÀS, lanes 4-6) or serum-free media and then switched back to serum-containing media for 30 min (ÀS/ þ FBS, lanes 7-9). The cell lysates were prepared and analysed for Akt phosphorylation. The expression of endogenous PHLPP was detected using the PHLPP1 and PHLPP2 antibodies. The phosphorylation of endogenous Akt was detected using the P473 antibody, whereas the total Akt was detected using the Akt antibody. Tubulin was probed with the g-tubulin antibody. The relative phosphorylation of Akt was obtained by normalizing ECL signals of P473 to those of total Akt and is indicated by the numbers below the P473 panel. The phosphorylation level of Akt in the control cells in serum was set to 1, and all other conditions were normalized accordingly. (c) Graphs showing the rate of proliferation in PHLPP knockdown cells. Two sets of experiments were performed to compare sh-P1-97 and sh-P2-60 or sh-P1-94 and sh-P2-59 to the control cells separately. Equal numbers of stable knockdown cells were seeded at day 0 in the regular growth medium. The cells were allowed to grow for additional 4 days, and the cell numbers were counted daily using a Coulter cell counter. For statistical analysis, the data obtained from the knockdown cells were compared to the control cells and the P-values were determined by two-sample t-tests. Data represent the mean ± s.e.m. (n ¼ 3, # Po0.001).
prevented on activation of the negative feedback loop (Brognard et al., 2007) . Moreover, reexpressing PHLPP significantly increases the sensitivity of colon cancer cells to PI3K inhibition. As more selective PI3K inhibitors are being developed clinically for cancer treatment, determining the expression level of PHLPP in cancer may help to predict which patients will respond to PI3K inhibition.
In determining the molecular mechanism underlying PHLPP-mediated inhibitory effect in colon cancer cells, our results reveal that PHLPP overexpression leads to dephosphorylation of p27 at the site required for nuclear localization (Liang and Slingerland, 2003) and upregulation of p27 protein. However, the expression level of other cell-cycle-related proteins such as cyclins is not affected by PHLPP overexpression ( Supplementary  Figure 2 ). p27 is a well-characterized negative regulator of the cell cycle and loss of p27 expression is strongly associated with colorectal cancer progression (Hershko and Shapira, 2006) . Previous studies have linked the loss TSC2 function to p27 downregulation (Rosner et al., 2006) , thus, this increase of p27 expression observed in PHLPP overexpressing cells is likely the result of reactivation of TSC2. Interestingly, different PHLPP isoforms affects different phases of the cell cycle. It has been shown that accumulation of p27 in Skp2 À/À mice results in cell-cycle defects at both the G 1 /S and G 2 /M transitions (Nakayama et al., 2004) . The distinct Figure 6 Overexpression of PHLPP (PH domain leucine-rich repeats protein phosphatase) isoforms reduces the tumorigenic potential of colon cancer cells in vivo. (a) Nude mice of BALB/c background were inoculated subcutaneously with HCT-Con, HCT-P1 and HCT-P2 cells. The size of the tumors was measured every 3-5 days. Four mice were used in each group, and the cells were inoculated at two sites in each mouse. Thus, eight tumors were measured and averaged in each group. Data in the graph represent the mean ± s.e.m., and the analysis was based on a longitudinal model to account for repeated measurements with each mouse (the asterisk indicates Po0.0001 for both HCT-P1 and HCT-P2 compared to HCT-Con). Representative tumors isolated from each group are shown below the graph, and the gray bar in the picture represents 1 cm. (b) The rate of cell proliferation was decreased in tumors derived from PHLPP expressing cells. The tumors isolated from mice injected with HCT-Con, HCT-P1 or HCT-P2 cells were fixed, sectioned and stained with the anti-Ki67 antibody. The Ki67-positive cells were viewed and counted under a microscope using the Â 10 objective. The numbers from four random viewing fields were averaged, and representative images are shown. Data in the graph represent the mean ± s.e.m. (n ¼ 4, *Po0.05). (c) The phosphorylation status of Akt in tumors derived from HCT116 stable cells. The tissue sections from the tumors formed by HCT-Con, HCT-P1 or HCT-P2 cells were stained with the PHLPP1 (upper panels), PHLPP2 (middle panels) or P473 (lower panels) antibodies. For P473-stained sections, the areas enclosed by the blue boxes in the top panels were enlarged and shown directly below. localization pattern of each PHLPP, as observed in normal epithelial cells (Figure 1) , may account for this differential effect. Given the existence of abundant phosphoproteins in cells and the limited numbers of protein phosphatases available, each PHLPP isoform is likely to have other yet to be identified substrates that also contribute to the final functional outcome.
In this study, we demonstrate that overexpression of either PHLPP isoform inhibits tumor formation in nude mice largely by reducing the rate of cell proliferation, as expression of PHLPP alone is insufficient to induce cell death (data not shown). However, previous studies have shown that overexpression of PHLPP promotes apoptosis in H157 and breast cancer cells (Gao et al., 2005; Brognard et al., 2007) . This differential effect of PHLPP in different cancer cells may depend on the genetic background unique to each cell type. For example, the colon cancer cells used in this study are known to have activated Wnt pathway. The expression of Akt isoforms in different cancer cells may also have a function in determining the functional outcome of PHLPP. Unlike H157 cells, the predominant Akt isoform expressed in colon cancer cells is Akt1, whereas only a very small amount of Akt2 (less than 5% of Akt1) and no Akt3 are detected ( Supplementary Figure 3a ; Samuels et al., 2005) . Akt1 was dephosphorylated in PHLPP expressing cells whereas the phosphorylation of Akt2 was below the detection limit ( Supplementary Figure 3b) . Future studies are needed to determine how PHLPP utilizes different signaling components downstream of Akt and interplays with other signaling pathways in different cancers. In summary, this study identified both PHLPP isoforms as tumor suppressors in human colorectal cancer. The findings here provide a novel mechanism by which the tumorigenesis process of colon cancer is inhibited by PHLPP-mediated termination of oncogenic signals directly.
Materials and methods
Antibodies
The anti-PHLPP1 and anti-PHLPP2 antibodies were obtained from Bethyl Laboratory (Montgomery, TX, USA). The following antibodies were from Cell Signaling (Danvers, MA, USA): rabbit antibodies against Akt (detect total Akt protein), phospho-Akt (P473 for the Ser473 site and P308 for the Thr308 site), phospho-GSK3a/b (Ser21/Ser9) and phospho-Tuberin/TSC2 (Thr1462). Rabbit antibodies against PKC bII and PKC-z were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-g-tubulin antibody was from Sigma-Aldrich (St Louis, MO, USA). Rabbit antibodies against phospho-p27 (T157 site) and total p27 were from R&D Systems (Minneapolis, MN, USA).
Immunohistochemical staining
Paraffin-embedded normal and colorectal cancer tissue section slides were obtained from the tissue bank of Sealy Center for Cancer Cell Biology at UTMB and US Biomax (Rockville, MD, USA). The tissue sections were deparaffinized, rehydrated and treated with hydrogen peroxide. Antigen retrieval was performed using Dako Target Retrieval Solution (Dako-Cytomation, Carpinteria, CA, USA) in a steamer. The sections were first blocked with avidin, biotin, and 5% normal goat serum and then incubated in a humidified chamber at 4 1C overnight with antibodies against PHLPP1 (1:500), PHLPP2 (1:500), P473 (1:50) or Ki67 (1:250). The samples were then incubated with biotin-labeled goat anti-rabbit secondary antibody and subsequently with horseradish peroxidase-avidin complex (Vector Laboratories, Burlingame, CA, USA). The staining was visualized using 3-amino-9-ethylcarbazol substrate solution, and the sections were then counterstained with hematoxylin. The stained sections were visualized using a Nikon DXM1200 microscope. Scoring of PHLPP staining was done blindly according to the intensity of staining with a fourtier system (levels 0-3; Reiner et al., 1990) .
Generation of PHLPP overexpressing stable cell lines
The colon cancer cell lines HCT116 and HT29 were cultured in McCoy's 5A media (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 1% penicillin/streptomycin. The cells were transfected with hemagglutinin-tagged PHLPP in the pcDNA/ 4-TO vector or the empty vector and subsequently selected with Zeocin (Invitrogen; 200 mg/ml). The resulting PHLPP overexpressing stable cells were termed HCT-P1, HCT-P2, HT29-P1 and HT29-P2, and the control cell lines HCT-Con and HT29-Con.
Lentivirus-mediated delivery of shRNA
The shRNAs for human PHLPP1 and PHLPP2 genes used in this study were constructed in pLKO.1-puro vector and purchased from Sigma-Aldrich (Stewart et al., 2003) . Two constructs for each gene were chosen for this study, and the targeting sequences are as the following: for PHLPP1, no. 94: CCTGATAGTATCATCTGTGAA, and no. 97: CGAGGTC TTTCCCGAAGTTAT; and for PHLPP2, no. 59: CCTCTTC AGATCGTTTATGAT, and no. 60: GCCTGAACTTGTCC CATAATA. A plasmid carrying a non-targeting sequence was used to create the control cells. For virus packaging, the control or PHLPP-specific shRNA constructs were cotransfected with Mission lentiviral packing mix (Sigma-Aldrich) into 293T cells using FuGene 6. The virus-containing media were collected, filtered and overlaid onto DLD1 cells in the presence of polybrene (8 mg/ml) for 24 h. The infected cells were then subjected to selection with puromycin (4 mg/ml).
Cell proliferation assay
To determine the rate of proliferation, equal numbers of cells were seeded into 12-well plates (2 Â 10 4 cells per well). The numbers of cells were counted daily for 4 days using a cell counter (Beckman-Coulter, Fullerton, CA, USA). For the rescue experiments and the experiments including the PI3K inhibitor, the cells were seeded into 12-well plates and allowed to grow for an additional 72 h. At the end of the experiments, the cells were fixed and stained with 0.5% crystal violet in 20% methanol for 30 min. After washing with water, the stained cells were dissolved in 1% SDS and absorbance at 570 nm was determined.
Cell-cycle analysis
The cells grown in the regular growth or the serum-free media for 24-36 h were collected, fixed in methanol and stained with propidium iodide (25 mg/ml) as described previously (Gao et al., 2005) . The cells were then subjected to the flow cytometry analysis. Quantification of the percentage cells in each cell cycle was obtained with Becton Dickinson FACSort (Franklin Lakes, NJ, USA).
Western blotting
The cells were collected and resuspended in lysis buffer (50 mM Na 2 HPO 4 , 1 mM sodium pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, 1 mM DTT, 200 mM benzamidine, 40 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride). The detergent-solubilized cell lysate was obtained by centrifuging in a microcentrifuge at 16 000 g for 5 min. The ECL signals were detected and quantified using a FluoChem digital imaging system (Alpha Innotech, San Leandro, CA, USA).
Tumorigenesis analysis in xenografted nude mice
The stable HCT116 cells were collected in phosphate-buffered saline and inoculated subcutaneously into 6-week-old female BALB/c-nu/nu mice at 1 Â 10 6 cells per injection site. The tumor size was measured every 3-5 days with a caliper, and the tumor volume was defined as (longest diameter) Â (shortest diameter) 2 /2. At the end of experiments, the mice were killed and the tumors dissected from the individual mouse were fixed in 10% buffered formalin. The paraffin-embedded samples were prepared, and 5 mm sections were used for IHC staining. All animal procedures were done in the nude mouse facility using protocols approved by the UTMB Animal Care and Use Committee.
Statistical analysis
The results from the experiments to assess the rate of proliferation, G 1 /S ratio, numbers of cells in G 2 and numbers of Ki-67-positive cells were summarized using mean ± s.e.m. and pairwise comparisons were carried out using two-sample t-tests. IHC intensity staining scores (0-3) of PHLPP1 and PHLPP2 in patient specimens were dichotomized into low (0-1) or high (2-3) expression in normal and tumor tissues. Comparisons were performed using the Wilcoxon rank-sum test for intensity scores or the w 2 -test for dichotomized PHLPP IHC expression levels. Spearman's coefficient was calculated to assess the correlation in intensity scores between the two PHLPP isoforms. Tumor growth in nude mice studies was summarized at each time point of follow-up and analysis was performed using longitudinal models to account for repeatedly measured tumor volume over time within each mouse.
